AU2004245184B2 - Phl p 5a derivatives with reduced allergenicity and retained T-cell reactivity - Google Patents
Phl p 5a derivatives with reduced allergenicity and retained T-cell reactivity Download PDFInfo
- Publication number
- AU2004245184B2 AU2004245184B2 AU2004245184A AU2004245184A AU2004245184B2 AU 2004245184 B2 AU2004245184 B2 AU 2004245184B2 AU 2004245184 A AU2004245184 A AU 2004245184A AU 2004245184 A AU2004245184 A AU 2004245184A AU 2004245184 B2 AU2004245184 B2 AU 2004245184B2
- Authority
- AU
- Australia
- Prior art keywords
- allergen
- variant
- phi
- group
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000009257 reactivity Effects 0.000 title claims abstract description 31
- 230000002829 reductive effect Effects 0.000 title claims abstract description 22
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 19
- 230000000717 retained effect Effects 0.000 title claims description 6
- 239000013566 allergen Substances 0.000 claims abstract description 96
- 241001330029 Pooideae Species 0.000 claims abstract description 22
- 239000013604 expression vector Substances 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000003259 recombinant expression Methods 0.000 claims abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 52
- 230000007815 allergy Effects 0.000 claims description 50
- 208000026935 allergic disease Diseases 0.000 claims description 41
- 108020004414 DNA Proteins 0.000 claims description 23
- 102000053602 DNA Human genes 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000011238 DNA vaccination Methods 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102100028572 Disabled homolog 2 Human genes 0.000 claims 1
- 101710197163 Disabled homolog 2 Proteins 0.000 claims 1
- 101000963860 Phleum pratense Pollen allergen Phl p 5.0101 Proteins 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 6
- 238000009169 immunotherapy Methods 0.000 abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 238000012217 deletion Methods 0.000 description 54
- 230000037430 deletion Effects 0.000 description 54
- 229960004784 allergens Drugs 0.000 description 33
- 150000001413 amino acids Chemical group 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000027455 binding Effects 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 206010048908 Seasonal allergy Diseases 0.000 description 15
- 229940046528 grass pollen Drugs 0.000 description 15
- 201000004338 pollen allergy Diseases 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000003651 basophil Anatomy 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 241000746983 Phleum pratense Species 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 241000209048 Poa Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002009 allergenic effect Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 240000004296 Lolium perenne Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 241000209049 Poa pratensis Species 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 229940074608 allergen extract Drugs 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 241001605702 Mylothris Species 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100282369 Caenorhabditis elegans gcc-2 gene Proteins 0.000 description 1
- 101100316805 Caenorhabditis elegans spe-5 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 101150105088 Dele1 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10325508 | 2003-06-04 | ||
| DE10325508.7 | 2003-06-04 | ||
| PCT/EP2004/004848 WO2004108758A1 (de) | 2003-06-04 | 2004-05-06 | Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004245184A1 AU2004245184A1 (en) | 2004-12-16 |
| AU2004245184B2 true AU2004245184B2 (en) | 2011-03-24 |
Family
ID=33494849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004245184A Ceased AU2004245184B2 (en) | 2003-06-04 | 2004-05-06 | Phl p 5a derivatives with reduced allergenicity and retained T-cell reactivity |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8628946B2 (enExample) |
| EP (3) | EP2272863B1 (enExample) |
| JP (2) | JP4782671B2 (enExample) |
| CN (1) | CN1798763B (enExample) |
| AT (1) | ATE513848T1 (enExample) |
| AU (1) | AU2004245184B2 (enExample) |
| BR (1) | BRPI0410908A (enExample) |
| CA (1) | CA2528053C (enExample) |
| ES (3) | ES2397778T3 (enExample) |
| PL (2) | PL2287180T3 (enExample) |
| PT (3) | PT2272863E (enExample) |
| RU (1) | RU2368620C2 (enExample) |
| WO (1) | WO2004108758A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR779201A0 (en) | 2001-09-20 | 2001-10-11 | University Of Melbourne, The | Immunotherapeutic and immunoprophylactic reagents |
| US8628946B2 (en) * | 2003-06-04 | 2014-01-14 | Merck Patent Gmbh | Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP3170510A1 (de) * | 2010-01-14 | 2017-05-24 | Merck Patent GmbH | Varianten der gruppe 5-allergene der süssgräser mit reduzierter allergenität durch mutagenese von prolinresten |
| US20230242922A1 (en) | 2021-09-13 | 2023-08-03 | Life Technologies Corporation | Gene editing tools |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19713001A1 (de) * | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung |
| WO2003025009A1 (en) * | 2001-09-20 | 2003-03-27 | The University Of Melbourne | RECOMBINANT ALLERGEN WITH REDUCED IgE BINDING BUT UNDIMINISHED T-CELL ANTIGENICITY |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736362A (en) * | 1990-10-26 | 1998-04-07 | The University Of Melbourne | Ryegrass pollen allergen |
| DE19918682A1 (de) | 1999-04-23 | 2000-10-26 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens |
| IT1318692B1 (it) | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche di phleum pratense. |
| DE60136653D1 (de) * | 2000-11-16 | 2009-01-02 | Alk Abello As | Mutante allergene |
| US8628946B2 (en) * | 2003-06-04 | 2014-01-14 | Merck Patent Gmbh | Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity |
-
2004
- 2004-05-06 US US10/559,272 patent/US8628946B2/en not_active Expired - Fee Related
- 2004-05-06 ES ES10009855T patent/ES2397778T3/es not_active Expired - Lifetime
- 2004-05-06 EP EP10009855A patent/EP2272863B1/de not_active Expired - Lifetime
- 2004-05-06 RU RU2005141524/13A patent/RU2368620C2/ru not_active IP Right Cessation
- 2004-05-06 ES ES04739147T patent/ES2367633T3/es not_active Expired - Lifetime
- 2004-05-06 ES ES10009856T patent/ES2434720T3/es not_active Expired - Lifetime
- 2004-05-06 CN CN200480015311XA patent/CN1798763B/zh not_active Expired - Fee Related
- 2004-05-06 JP JP2006508164A patent/JP4782671B2/ja not_active Expired - Fee Related
- 2004-05-06 PL PL10009856T patent/PL2287180T3/pl unknown
- 2004-05-06 EP EP04739147A patent/EP1629006B1/de not_active Expired - Lifetime
- 2004-05-06 EP EP10009856.5A patent/EP2287180B9/de not_active Expired - Lifetime
- 2004-05-06 PL PL10009855T patent/PL2272863T3/pl unknown
- 2004-05-06 WO PCT/EP2004/004848 patent/WO2004108758A1/de not_active Ceased
- 2004-05-06 AT AT04739147T patent/ATE513848T1/de active
- 2004-05-06 PT PT100098557T patent/PT2272863E/pt unknown
- 2004-05-06 BR BRPI0410908-2A patent/BRPI0410908A/pt not_active IP Right Cessation
- 2004-05-06 CA CA2528053A patent/CA2528053C/en not_active Expired - Fee Related
- 2004-05-06 PT PT04739147T patent/PT1629006E/pt unknown
- 2004-05-06 PT PT100098565T patent/PT2287180E/pt unknown
- 2004-05-06 AU AU2004245184A patent/AU2004245184B2/en not_active Ceased
-
2010
- 2010-09-16 JP JP2010207438A patent/JP5363441B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-02 US US14/146,364 patent/US9522938B2/en not_active Expired - Fee Related
-
2016
- 2016-04-05 US US15/090,935 patent/US20160207967A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19713001A1 (de) * | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung |
| WO2003025009A1 (en) * | 2001-09-20 | 2003-03-27 | The University Of Melbourne | RECOMBINANT ALLERGEN WITH REDUCED IgE BINDING BUT UNDIMINISHED T-CELL ANTIGENICITY |
Non-Patent Citations (1)
| Title |
|---|
| SCHRAMM, GABRIELE et al. '"Allergen Engineering": Variants of the Timothy Grass Pollen Allergen Ph1 p 5b with Reduced IgE-Binding Capacity but Conserved T cell reactivity.' The Journal of Immunology. 1999, Vol. 162, pages 2406-2414 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160207967A1 (en) | Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity | |
| US5693495A (en) | Allergens of alder pollen and applications thereof | |
| US20150079120A1 (en) | Dna sequence and preparation of grass pollen allergen phl p4 by recombinant methods | |
| US7241450B1 (en) | DNA sequence and recombinant production of a Gramineae allergen | |
| US8263090B2 (en) | Variants of group 1 allergens from Poaceae having reduced allergenicity and maintained T-cell reactivity | |
| AU2010342533B2 (en) | Variants of the group-5 allergens of the poaceae with reduced allergenicity by mutagenesis of proline residues | |
| US8999348B2 (en) | Variants of group 6 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues | |
| AU2012205288B2 (en) | DNA-sequence and recombinant production of group 4 major allergens from cereals | |
| AU2013204574B2 (en) | DNA-sequence and recombinant production of group 4 major allergens from cereals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |